Online citations, reference lists, and bibliographies.
← Back to Search

Cisplatin And Vinorelbine First-line Chemotherapy In Non-resectable Malignant Pleural Mesothelioma

J. Sørensen, H. Frank, T. Palshof
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically verified malignant pleural mesothelioma (MPM), normal organ function, and performance status 0–2. Treatment was vinorelbine 25 mg m−2 i.v. weekly and cisplatin 100 mg m−2 i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment. Patients gave written informed consent. Characteristics of 54 consecutive patients were: males 85%, epithelial subtype 74%, IMIG stages III and IV 35 and 46%, performance status 0, 1, and 2, 26, 69, and 6%, and median age 63 years (31–78 years). CTC grade 3 or 4 toxicity occurred with respect to leukocytopenia (48% of patients, grade 4 in 13%), nausea (13%), neurotoxicity (11%), nephrotoxicity (4%), and other toxicities (9%). There were no toxic deaths. The median number of cycles was four. The fraction of patients alive at 1-, 2-, and 3-years were 61, 31, and 4%, respectively, and median survival and median time to progression were 16.8 months (0.5 to 46.4 +months) and 7.2 months (1.6 to 40.6 + months). There were two CRs and 14 PRs (response rate 29.6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.
This paper references
10.1016/J.LUNGCAN.2006.09.023
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
C. Obasaju (2007)
Malignant pleural
R Libener (2006)
[Phase II study].
H. Niitani (1995)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
Phase II study of Pemetrexed plus Carboplatin
A Santoro (2006)
10.1002/14651858.CD004797.PUB4
Multisystemic Therapy for social, emotional, and behavioral problems in youth aged 10-17.
J. Littell (2005)
10.1016/S0169-5002(03)91714-4
O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma
M. Boyer (2003)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Cisplatin and gemcitabine treatment for malignant pleural mesothelioma : a phase II study
MJ Byrne (1999)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1016/J.LUNGCAN.2004.04.020
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
S. Tomek (2004)
Symptom and quality of life advantages for pemetrexed+Cisplatin versus Cisplatin alone in treatment of malignant pleural Mesothelioma
Mj Boyer (2003)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
Symptom and quality of life advantages for pemetrexed + Cisplatin versus Cisplatin alone in treatment of malignant pleural Mesothelioma
MJ Boyer (2003)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant (MPM): Results of the International Expanded Access Program (EAP)
A Santoro (2007)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1200/JCO.2007.25.18_SUPPL.LBA7525
A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: First results of the Medical Research Council (MRC) / British Thoracic Society (BTS) MS01 trial
M. Muers (2007)
Cisplatin and gemcitabine treatment
NH (1999)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1016/J.LUNGCAN.2003.07.005
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
F. Monetti (2004)
10.1200/JCO.2004.22.90140.7021
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC.
J. Van Meerbeeck (2004)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1038/sj.bjc.6600673
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
S. Tomek (2003)
10.1111/j.1752-699X.2008.00046.x
Current concepts in chemotherapy for malignant pleural mesothelioma
J. Sørensen (2008)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2005.03.3027
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
A. Bottomley (2006)
Modified RECIST criteria for assessment
MJ Byrne (2004)
10.1016/0021-9681(61)90060-1
The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.
E. Gehan (1961)
Symptom and quality of life
MJ Boyer (2003)
10.1200/JCO.1998.16.7.2459
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
A. Wozniak (1998)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Activity of chemotherapy and immuno
AP Meert (2002)
British Journal of Cancer Cancer Research UK Clinical Studies
(2008)
10.1016/S0959-8049(00)00072-1
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
P. Rougier (2000)
10.1016/J.LUNGCAN.2005.05.007
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
T. Berghmans (2005)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1200/JCO.2007.25.18_SUPPL.7562
Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant pleural mesothelioma (MPM): Results of the International Expanded Access Program (EAP)
A. Santoro (2007)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/S0093-7754(02)70044-4
Emerging insights into the biology and therapy of malignant mesothelioma.
N. Vogelzang (2002)
10.1200/JCO.1994.12.2.360
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
T. Le Chevalier (1994)
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced nonsmall-cell lung cancer: A Southwest Oncology Group study
AJ Wozniak (1998)
10.1093/ANNONC/MDH356
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
E. Andreopoulou (2004)
The palliative benefits of MVP
A Norton (2004)



This paper is referenced by
10.1517/14728210903074563
Malignant pleural mesothelioma: current treatments and emerging drugs
C. Belli (2009)
10.1038/bjc.2012.44
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
Ó. Arrieta (2012)
Mesothelioma: a review.
F. Mott (2012)
10.1053/j.semtcvs.2009.06.010
Current options for systemic therapy in mesothelioma.
D. Jackman (2009)
10.1016/j.critrevonc.2010.04.004
Malignant pleural mesothelioma: the standard of care and challenges for future management.
J. Van Meerbeeck (2011)
10.1097/JTO.0b013e318233d6a9
Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival
Z. G. Zimling (2012)
10.2217/fon.09.7
Malignant pleural mesothelioma.
R. Stahel (2009)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1007/s10405-009-0350-0
Therapie des malignen Pleuramesothelioms
Hanno Huwer (2009)
10.1016/j.lungcan.2009.03.016
Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
O. Røe (2010)
10.1586/era.09.2
Future developments in the management of malignant pleural mesothelioma
Paolo Andrea Zucali (2009)
10.1016/j.lungcan.2009.04.008
COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
S. O'Kane (2010)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
C. C. Boons (2013)
10.1007/s00280-014-2429-5
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma
O. Arrieta (2014)
10.1007/s00280-012-1965-0
A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma
Z. G. Zimling (2012)
10.2478/v10019-012-0032-0
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
V. Kovač (2012)
An Update on Biomarkers and Treatment
Mandira Ray (2015)
10.1016/j.ctrv.2015.10.006
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
G. Ceresoli (2015)
10.1515/pp-2016-0013
Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma
Adam Szulkin (2016)
10.1097/JTO.0b013e3181d86ea9
Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma: A Review and Case Report
C. Bech (2010)
10.1097/CCO.0b013e328324bc30
Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?
R. Stahel (2009)
Malignantpleuralmesothelioma: currenttreatmentsandemerging drugs
Carmen Belli (2009)
In vitro testing of drug sensitivity in tumor cells from effusion
Carl-Olof Hillerdal (2017)
10.1007/s00280-011-1655-3
Review on clinical trials of targeted treatments in malignant mesothelioma
J. N. Jakobsen (2011)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
Best evidence topic - Thoracic oncologic Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
Sumera Sharif (2011)
10.1111/j.1743-7563.2010.01316.x
Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia
A. Hasani (2010)
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Z. G. Zimling (2015)
10.1510/icvts.2010.256289
Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?
S. Sharif (2011)
A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma.
M. Higashiguchi (2012)
10.1007/s10405-009-0351-z
Therapie des malignen Pleuramesothelioms
S. Gütz (2009)
10.1002/pbc.21718
Treatment of peritoneal mesothelioma in pediatric patients
L. Cioffredi (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar